Investor group pushes big pharma to report links between pricing and executive compensation | Becker’s Hospital Review

A group of institutional investors, with more than $400 billion of assets, is urging big pharmaceutical manufacturers to begin reporting links between drug pricing strategies and executive compensation, according to Bloomberg.

The Interfaith Center on Corporate Responsibility, submitted shareholder proposals at the annual meetings of Abbvie, Amgen, Biogen, Bristol Myers Squibb and Eli Lilly Co. to demand compiled reports about the risks of high drug prices, while also examining the connection between pricing strategies and executive compensation, reports STAT.

Read complete article here:

Investor group pushes big pharma to report links between pricing and executive compensation.

Post a Comment

WP-SpamFree by Pole Position Marketing